Screener
Axsome Therapeutics AXSM Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Axsome Therapeutics’s 10-Q, filed August 10, 2026. Open the filing →
- Filed
- Aug 10, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-342360
FAQ
- What is Axsome Therapeutics's net income?
- Axsome Therapeutics (AXSM) reported net income of -$51.31M in Q2 2026.
- How has Axsome Therapeutics's net income changed year-over-year?
- Axsome Therapeutics's net income decreased by 7.0% year-over-year, from -$47.97M to -$51.31M.
- What is the long-term trend for Axsome Therapeutics's net income?
- Over 4 years (2021 to 2025), Axsome Therapeutics's net income has grown at a 8.9% compound annual growth rate (CAGR), from -$130.4M to -$183.17M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Axsome Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude